These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 35987165)

  • 1. Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
    Simonelli M; Garralda E; Eskens F; Gil-Martin M; Yen CJ; Obermannova R; Chao Y; Lonardi S; Melichar B; Moreno V; Yu ML; Bongiovanni A; Calvo E; Rottey S; Machiels JP; Gonzalez-Martin A; Paz-Ares L; Chang CL; Mason W; Lin CC; Reardon DA; Vieito M; Santoro A; Meng R; Abbadessa G; Menas F; Lee H; Liu Q; Combeau C; Ternes N; Ziti-Ljajic S; Massard C
    ESMO Open; 2022 Oct; 7(5):100562. PubMed ID: 35987165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
    Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
    Carlo-Stella C; Zinzani PL; Sureda A; Araújo L; Casasnovas O; Carpio C; Yeh SP; Bouabdallah K; Cartron G; Kim WS; Cordoba R; Koh Y; Re A; Alves D; Chamuleau M; Le Gouill S; López-Guillermo A; Moreira I; van der Poel MWM; Abbadessa G; Meng R; Ji R; Lépine L; Saleem R; Ribrag V
    Hematol Oncol; 2023 Feb; 41(1):108-119. PubMed ID: 36251503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
    Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ
    Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
    Sherman E; Lee JL; Debruyne PR; Keam B; Shin SJ; Gramza A; Caro I; Amin R; Shah K; Yan Y; Huddart R; Powles T
    ESMO Open; 2023 Apr; 8(2):100877. PubMed ID: 36947985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
    Cho BC; Abreu DR; Hussein M; Cobo M; Patel AJ; Secen N; Lee KH; Massuti B; Hiret S; Yang JCH; Barlesi F; Lee DH; Ares LP; Hsieh RW; Patil NS; Twomey P; Yang X; Meng R; Johnson ML
    Lancet Oncol; 2022 Jun; 23(6):781-792. PubMed ID: 35576957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CX-072 (pacmilimab), a Probody
    Naing A; Thistlethwaite F; De Vries EGE; Eskens FALM; Uboha N; Ott PA; LoRusso P; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Randhawa M; Durm G; Gil-Martin M; Stroh M; Hannah AL; Arkenau HT; Spira A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
    Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
    BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial.
    Crabb S; Wickens R; Jane-Bibby S; Dunkley D; Lawrence M; Knight A; Jones R; Birtle A; Huddart R; Linch M; Martin J; Coleman A; Boukas K; Markham H; Griffiths G
    BMC Cancer; 2023 Sep; 23(1):885. PubMed ID: 37726695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial.
    Colevas AD; Bahleda R; Braiteh F; Balmanoukian A; Brana I; Chau NG; Sarkar I; Molinero L; Grossman W; Kabbinavar F; Fassò M; O'Hear C; Powderly J
    Ann Oncol; 2018 Nov; 29(11):2247-2253. PubMed ID: 30219915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
    Spigel DR; Chaft JE; Gettinger S; Chao BH; Dirix L; Schmid P; Chow LQM; Hicks RJ; Leon L; Fredrickson J; Kowanetz M; Sandler A; Funke R; Rizvi NA
    J Thorac Oncol; 2018 Nov; 13(11):1733-1742. PubMed ID: 29775807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
    Martin TG; Shah N; Richter J; Vesole DH; Wong SW; Huang CY; Madduri D; Jagannath S; Siegel DS; Biran N; Wolf JL; Parekh S; Cho HJ; Munster P; Richard S; Ziti-Ljajic S; Chari A
    Cancer; 2021 Jun; 127(11):1816-1826. PubMed ID: 33735504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
    Yamamoto N; Kitano S; Koyama T; Ikeda M; Mizugaki H; Narikiyo T; Yamaguchi Y; Ishida T; Takubo R; Ogami C; Sekiya M; Nakagawa Y; Kuboki Y
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39053945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
    Lesokhin A; LeBlanc R; Dimopoulos MA; Capra M; Carlo-Stella C; Karlin L; Castilloux JF; Forsberg P; Parmar G; Tosikyan A; Pour L; Ribrag V; Ribolla R; Abdallah AO; Le Roux N; Dong L; van de Velde H; Mayrargue L; Lépine L; Macé S; Moreau P
    Cancer Med; 2023 May; 12(9):10254-10266. PubMed ID: 36866838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
    Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.